Ensign Peak Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-212,423
Closed -$7.2M – 1769
2026
Q2
$7.2M Sell
212,423
-36,767
-15% -$1.21M 0.01% 493
2026
Q1
$7.98M Sell
249,190
-300,321
-55% -$9.8M 0.01% 453
2025
Q4
$19.3M Buy
+549,511
New +$20M 0.03% 297
2024
Q4
– Sell
-245,571
Closed -$4.08M – 1721
2024
Q3
$4.08M Sell
245,571
-535
-0.2% -$9.26K 0.01% 697
2024
Q2
$4.73M Hold
246,106
– – 0.01% 636
2024
Q1
$5.82M Buy
246,106
+54,150
+28% +$1.1M 0.01% 587
2023
Q4
$2.14M Sell
191,956
-245,777
-56% -$2.25M ﹤0.01% 891
2023
Q3
$4.05M Sell
437,733
-4,223
-1% -$45.7K 0.01% 629
2023
Q2
$5.25M Buy
441,956
+86,956
+24% +$1.15M 0.01% 570
2023
Q1
$4.71M Hold
355,000
– – 0.01% 584
2022
Q4
$3.87M Buy
+355,000
New +$3.53M 0.01% 624

Other funds holding NAMS

Ensign Peak Advisors's NAMS Position: Q3 2026 in Review

Ensign Peak Advisors sold out of NewAmsterdam Pharma (NAMS) in Q3 2026, closing a stake of 212,423 shares — an estimated $7.2M sold.

Ensign Peak Advisors first reported a position in NAMS in Q4 2022 and held it in 11 quarters. The position peaked at $19.3M in Q4 2025. 183 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

  • Ensign Peak Advisors reported no remaining NewAmsterdam Pharma position as of Q3 2026 after selling out during the quarter.
  • Ensign Peak Advisors sold 212,423 NewAmsterdam Pharma shares in Q3 2026, an estimated $7.2M.
  • Ensign Peak Advisors first reported a position in NewAmsterdam Pharma in Q4 2022 and held it in 11 quarters.
  • Ensign Peak Advisors's NewAmsterdam Pharma position peaked at $19.3M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.